je.st
news
Mercks 9-Valent HPV Vaccine, GARDASIL9, Recommended by CDCs Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21
2015-02-26 21:18:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use of HPV vaccines. GARDASIL 9 has been added to the routine recommendations for vaccination of 11- and 12- year-old females and males. The vaccination series can be started at age nine. Language: English Contact: Media:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913Investor:Justin Holko, 908-740-1879Amy Klug, 908-740-1898 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/83723ae8-8ced-4eba-af3f-282064c0e25f_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-83723ae8-8ced-4eba-af3f-282064c0e25f"); Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: recommended
committee
practices
advisory
Category:Biotechnology and Pharmaceuticals